Altimmune 2023 annual meeting results: all director nominees elected, say-on-pay approved

Proposal No. 5 : Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 27,712,554 ​ 6,744,992 104,432

Proposal No. 1 : Election of Directors. The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Broker Director ​ For ​ Withhold ​ Non-Votes Mitchel Sayare, Ph.D., Chairman ​ 21,844,990 316,470 12,400,518 Vipin K. Garg, Ph.D. ​ 21,885,151 276,309 12,400,518 David J. Drutz, M.D. ​ 19,880,376 2,281,084 12,400,518 John M. Gill ​ 21,588,792 572,668 12,400,518 Philip L. Hodges ​ 21,810,125 351,335 12,400,518 Diane Jorkasky, M.D. ​ 21,824,133 337,327 12,400,518 Wayne Pisano ​ 19,385,875 2,775,585 12,400,518 Klaus O. Schafer, M.D., MPH 21,823,016 338,444 12,400,518 Catherine Sohn, Pharm D 21,912,287 249,173 12,400,518

Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 34,318,768 ​ 153,149 90,061

Proposal No. 3 : Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ For ​ Against ​ Abstain ​ Broker Non-Votes 16,834,432 ​ 5,221,648 ​ 105,380 12,400,518

Proposal No. 4 : Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "frequency of say-on-pay" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 1 Year ​ 2 Years ​ 3 Years ​ Abstain ​ Broker Non-Votes 21,595,590 ​ 80,595 352,096 133,179 12,400,518